ArticleFrontiers in oncology2026
Nomogram-based prediction models for clinical outcomes in pediatric
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify prognostic factors and develop nomograms predicting short-term mortality and relapse in pediatric Methods: We retrospectively analyzed 136 pediatric patients with Results: High-Risk measurable residual disease (MRD), treatment regimen, and diagnostic white blood cell (WBC) group (≥20×10⁹/L vs. <20×10⁹/L) independently predicted OS. For RFS, independent predictors were percentage of bone marrow blasts by flow cytometry (BM blasts [FCM]), extramedullary infiltration (EMI), High-Risk MRD, treatment regimen, and WBC group. Nomograms demonstrated strong discrimination and calibration with superior clinical net benefit versus any single predictor. Nomogram-derived scores stratified patients into prognostically distinct subgroups with significant differences in OS and RFS. Conclusions: This study established internally validated 3-year OS and RFS nomograms for pediatric
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.